Rchr
J-GLOBAL ID:201801010690126455   Update date: Sep. 23, 2024

Yasuharu Akasaki

アカサキ ヤスハル | Yasuharu Akasaki
Affiliation and department:
Job title: Associate Professor
Research field  (1): Neurosurgery
Research keywords  (2): onco-immunology ,  neuro-oncology
Research theme for competitive and other funds  (4):
  • 2021 - 2024 Investigation of the effect and prediction factors of bevacizumab on immunoregulation in glioblastoma
  • 2010 - 2012 Immunotherapy with fusions of dendritic and glioma stem cells against malignant glioma
  • 2007 - 2008 Induction of active anti-glioma vaccine
  • 1998 - 2001 Anti-angiogenesis gene therapy utilizing viral vectors
Papers (46):
  • Yohei Yamamoto, Kyoichi Tomoto, Akihiko Teshigawara, Takuya Ishii, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Toshihide Tanaka. Significance and priority of surgical resection as therapeutic strategy based on clinical characteristics of brain metastases from renal cell carcinoma. World Neurosurgery. 2024
  • Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
  • Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
  • Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
  • Jun Takei, Yuko Kamata, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Tomoya Suzuki, Ayaka Oda, et al. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII. 2023
more...
MISC (22):
  • Yamamoto Y, Tanaka T, Takei J, Teshigawara A, Nawate S, Tohmoto K, Ishii T, Hasegawa Y, Akasaki Y, Murayama Y. MET-2 Clinical features of renal cell carcinoma brain metastases compared with other carcinomas. Neuro-Oncology Advances. 2023. 5. 5. v4-v4
  • Akasaki Y, Kikuchi T, Tanaka T, Murayama Y. Dendritic cell immunotherapy for malignant glioma: Research history for 25 years and the future perspectives. Neuro-Oncology Advances. 2022. 4. 3. iii27
  • Akasaki Y, Suzuki T, Takei J, Tanaka T, Mori R, Koseki H, Yamamoto Y, Teshigawara A, Kamata Y, Yanagisawa T, et al. Pros and cons of surgical intervention for diffuse midline glioma aimed at dendritic cell immunotherapy. Neuro-Oncology Advances. 2022. 4. 3. iii12
  • Yamamoto Y, Nawate S, Nakamura A, Ishii T, Tanaka T, Akasaki Y, Murayama Y. Analysis of metastatic brain tumors discovered at the same time as the primary lesion. Neuro-Oncology Advances. 2022. 4. 3. iii21-iii22
  • Tohmoto K, Yamamoto Y, Tanaka T, Suzuki T, Teshigawara A, Takei J, Koseki H, Mori R, Akasaki Y, Murayama Y. Clinical benefit of add-on bevacizumab for newly diagnosed glioblastoma in elderly patients with unresectable and poor performance status. Neuro-Oncology Advances. 2022. 4. 3. iii8
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page